Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
Prognostic impact of<i>DDX41</i>germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyNicolas Duployez, Marie Sébert, Hervé Dombret et al.|Blood|2022Cited by 80
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemiaNicolas Duployez, Claude Preudhomme, Hervé Dombret et al.|Leukemia|2023Cited by 30